Citations

Showing 10 of 108104 citations.

Baseline CSF phosphorylated tau as an indicator of subsequent tau accumulation on tau PET
Wiste, Heather J. , Weigand, Stephen D. , Lowe, Val J. , Therneau, Terry M. , Graff‐Radford, Jonathan , Gunter, Jeffrey L. , Petersen, Ronald C. , Cogswell, Petrice M. , Mielke, Michelle M. , Schwarz, Christopher G. , Knopman, David S. , Vemuri, Prashanthi , Senjem, Matthew L. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.052979 Get It

AbstractBackgroundAlzheimer’s disease biomarkers of tau pathology may be assessed by both CSF and PET. Cross‐sectional associations between CSF phosphorylated tau (p‐tau) and tau PET have been studied and regional tau PET SUVR has been shown to have similar diagnostic performance as CSF p‐tau. The association between CSF p‐tau and longitudinal tau PET has not been studied. CSF measures may be thought of as a result of the imbalance of influx vs efflux of soluble tau, whereas, tau PET reflects total tau accumulation into insoluble aggregates to date. We therefore hypothesize that baseline CSF p‐tau may be a leading indicator of future tau PET accumulation.MethodWe identified Mayo Clinic Study of Aging (MCSA) and Mayo Alzheimer’s Disease Research Center (ADRC) participants with diagnoses of cognitively unimpaired, mild cognitive impairment, and amnestic dementia who had CSF p‐tau (Elecsys p‐tau [181P]) and subsequent serial tau PET (flortaucipir) exams. The first tau PET scan was within 3 years of the CSF p‐tau collection. A longitudinal pipeline with two‐compartment partial volume correction was used to measure change in tau PET in a temporal‐lobe meta‐ROI (amygdala, fusiform, middle/inferior temporal, entorhinal, and parahippocampal regions) with a composite reference region (eroded supratentorial white matter, pons, and whole cerebellum). Spearman correlation was used to assess the association between CSF p‐tau and annual percent change in tau PET. A linear mixed effects model was fit to assess the association adjusting for age and sex.ResultThe study included 143 participants (76% cognitively unimpaired) (). CSF p‐tau was significantly associated with annual percent change in tau PET overall (Spearman R=0.19, p=0.023) () and after adjusting for age and sex (p<0.001) (). There was nonlinearity in the CSF p‐tau effect, with higher values (>20 pg/mL) having a greater association with annual change in tau PET than lower values.ConclusionIn a group of cognitively unimpaired and impaired participants, CSF p‐tau predicted subsequent tau PET accumulation rate. A threshold effect is suggested with subsequent tau PET accumulation primarily in participants with elevated CSF p‐tau levels near the Mayo threshold of 22 pg/mL.
The location of PSEN1 pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study
Fitzpatrick, Colleen , Chui, Helena C., Fagan, Anne M. , Farlow, Martin R. , Graff‐Radford, Neill R. , Mori, Hiroshi , Perrin, Richard J. , Salloway, Stephen , Xiong, Chengjie , Johnson, Keith A., Chhatwal, Jasmeer P. , DIAN, Schultz, Stephanie A. , Schultz, Aaron P. , Joseph‐Mathurin, Nelly , McDade, Eric , Klunk, William E. , Fox, Nick C. , Xiong, Chengjie , Hassenstab, Jason , Goate, Alison , Hanseeuw, Bernard , Lee, Jae‐Hong , Jucker, Mathias , Allegri, Ricardo , Benzinger, Tammie L.S. , Berman, Sarah , Chui, Helena C. , Cruchaga, Carlos , Gordon, Brian A. , Martins, Ralph N. , Noble, James M. , Sánchez‐Valle, Raquel , Schofield, Peter R. , Levey, Allan I. , Karch, Celeste M. , Johnson, Keith A. , Bateman, Randall J. , Sperling, Reisa Anne , DIAN

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.050864 Get It

AbstractBackgroundThough pathogenic variations in PSEN1 leading to Autosomal Dominant Alzheimer's disease (ADAD) are all highly penetrant, there is substantial inter‐individual variability in the rates of cognitive decline and biomarker change observed in ADAD. We hypothesized that this inter‐individual variability may be associated with the location of the pathogenic variant within PSEN1. We tested this hypothesis using biomarker and cognitive data from the Dominantly Inherited Alzheimer Network (DIAN) observational study.MethodPSEN1 pathogenic variant carriers [grouped based on whether their ADAD genotype affected transmembrane (PSEN1 TM; N = 125) or cytoplasmic (PSEN1 CY; N = 62) domains] and non‐carriers [NC; N = 176] enrolled in DIAN underwent clinical evaluation, multimodal neuroimaging, and lumbar puncture for collection of cerebrospinal fluid (CSF). Linear mixed effects models with a restricted cubic spline were used to determine cross‐sectional differences in clinical and biomarker measures between NC, PSEN1 TM, and PSEN1 CY groups, across the disease course (estimated years to symptom onset; EYO).ResultBackground characteristics are reported in Table 1. PSEN1 CY and PSEN1 TM groups had elevated β‐amyloid (PiB‐PET) and phosphorylated‐tau levels (CSF pTauT181) compared to NC, but these biomarker measures were not different between PSEN1 TM and CY groups (Figure 1a‐b). Additionally, the PSEN1 TM group had decreased glucose metabolism compared to NC but was similar to the PSEN1 CY group (Figure 1c). However, we observed that PSEN1 TM carriers had significantly smaller hippocampal volume, greater lateral ventricle volume, and greater cognitive impairment (Figure 1d‐f) across EYO as compared to PSEN1 CY carriers.ConclusionDespite similar β‐amyloid PET and CSF pTauT181 levels across EYO, individuals with pathogenic variants affecting transmembrane domains in PSEN1 may have more rapid progression of disease as measured by cognitive function and neurodegeneration as compared to those with variants affecting cytoplasmic domains. These results have implications both for understanding the heterogeneity in ongoing ADAD clinical trials and for better understanding the pathobiology of ADAD.
Comparison of Pittsburgh compound‐B and flutemetamol white matter binding
Przybelski, Scott A. , Lesnick, Timothy G. , Kantarci, Orhun H. , Kemp, Bradley J. , Kantarci, Kejal , Lowe, Val J. , Kantarci, Kejal , Zeydan, Burcu , Schwarz, Christopher G. , Kremers, Walter K. , Senjem, Matthew L. , Min, Hoon-Ki Paul , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S4 | Pages: No page available

10.1002/alz.050233 Get It

AbstractBackgroundWhite matter (WM) 11C‐Pittsburgh compound‐B (PiB) and 18F‐Flutemetamol (FMT) uptake is increasingly being used as a reference region to calculate the standard uptake value ratios (SUVr) in longitudinal amyloid‐β PET studies. PiB uptake is lower in WM hyperintensities (WMH) in older adults. Furthermore, WM PiB uptake increases with aging. Our objective was to determine whether a similar variation in WM uptake exists with an 18F‐ligand FMT.MethodA cohort of cognitively unimpaired (CU) older adults with median (range) age of 67 (61, 83) years (N=31), and younger adults with median (range) age of 38 (30, 48) years (N=30) from the community responding to a study advertisement underwent MRI, PiB and FMT PET. MRI‐FLAIR images were segmented into WMH and normal appearing white matter (NAWM) and registered to the T1‐weighted image. PiB and FMT PET images were registered to the T1‐weighted image. PiB and FMT SUVrs from the WMH and NAWM compartments were calculated using cerebellar crus uptake as a reference.ResultWMH PiB SUVr and NAWM PiB SUVr were lower in the younger compared to the older adults (p<0.001). WMH FMT SUVr and NAWM FMT SUVr were lower in younger compared to older adults (p<0.001). PiB SUVr was lower than FMT SUVr both in younger and older adults in both WMH and NAWM compartments (p<0.001). In both age groups, PiB SUVr and FMT SUVr in WMH was lower than NAWM (p<0.001). AUROC analysis demonstrated no difference between PiB versus FMT SUVr in differentiating WMH from NAWM in younger and older adults.ConclusionWMH and NAWM SUVRs are higher with FMT than PiB, however both PiB and FMT show a similar topographic pattern of uptake in the WM with higher uptake in NAWM compared to WMH. Aging is associated with a decrease in myelin integrity and increase of WMH volume. Higher WMH and NAWM PiB and FMT uptake in the older compared to younger adults suggests that additional aging‐related mechanisms are influencing WM PET tracer uptake. Age and WMH volume should be considered when WM uptake is used as a reference region for the evaluation of cortical uptake of both PiB and FMT.
Dementia friendly community outreach improves research participation and dementia resource utilization among African Americans
Lucas, John A. , Robinson, Maisha T. , Willis, Floyd B. , Parfitt, Francine, Fudge, Michelle R., Wainwright, Jolita D., Graff‐Radford, Neill R. , Bergeron, Caroline D.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.052088 Get It

AbstractBackgroundAfrican Americans are at greater risk of Alzheimer’s disease (AD) and AD‐related dementia (ADRD). They are also less likely to access dementia resources or participate in dementia research. The National Alzheimer’s Project Act (NAPA) calls for special attention to dementia‐related health disparities in high risk groups. Identifying effective tools to improve rates of dementia resource utilization and research participation by African Americans is essential to achieving dementia health equity.MethodTwo neighborhoods of Jacksonville, FL, defined by zip codes, were the focus of this study. Both zip codes have a large population of African American residents per 2010 US Census, and a history of hosting outreach activities by our Alzheimer’s Disease Research Center (ADRC). In one neighborhood, we modified the NAPA Dementia Friendly (DF) America toolkit to serve as a model of outreach. The second neighborhood served as a control (CON), in which we maintained our traditional outreach model of community‐based lectures. Primary outcome measures were: (1) enrollment in ADRC center‐related studies and (2) phone call volumes from individuals seeking dementia resource information. The outcomes in the DF and CON neighborhoods were compared via Fisher’s exact test to those in other zip codes in Jacksonville (OT).ResultIn the 18 months following implementation of the DF intervention, 54 African Americans enrolled in ADRC‐related research (19 DF, 3 CON, 32 OT), compared to 21 during the 18 months prior (2 DF, 0 CON, and 19 OT). The increase in DF residents enrolling in research following the intervention was statistically significant (p =0 .02) relative to OT residents. The increase observed in the CON residents was not statistically significant (p=1.0) compared to OT residents. Call volumes from African Americans increased from 13 prior to program implementation (all from OT) to 62 calls after implementation (22 DF, 1 CON, 39 OT). The increase among DF residents seeking information following the intervention was statistically significant (p =0.008) whereas the increase was not significant in the CON residents (p=0.54).ConclusionResults suggest that the NAPA DFA can be leveraged to improve dementia resource utilization and research participation among community‐dwelling African Americans.
Demographic and psychosocial factors associated with the decision to learn mutation status in familial frontotemporal dementia and the impact of disclosure on mood
Bajorek, Lynn, Kiekhofer, Rachel, Hall, Matthew J. , Taylor, Joanne, Lucente, Diane , Brushaber, Danielle , Coppolla, Giovanni, Bordelon, Yvette , Dickerson, Brad C., Fagan, Anne M. , Fields, Julie A. , Forsberg, Leah K. , Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Graff‐Radford, Jonathan, Grant, Ian , Heuer, Hilary W. , Huey, Edward D. , Kornak, John , Ljubenkov, Peter A. , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Miyagawa, Toji , Onyike, Chiadi U. , Pedraza, Otto , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Savica, Rodolfo , Toga, Arthur W. , Weıntraub, Sandra , Boxer, Adam L. , Rosen, Howard J. , Staffaroni, Adam M. , Hall, Matthew, Appleby, Brian S. , Botha, Hugo , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , McMillan, Corey T. , Miller, Bruce L. , Pascual, Belén , Rexach, Jessica E. , Roberson, Erik D. , Rojas, Julio C. , Seeley, William W. , Tartaglia, Maria Carmela , Wong, Bonnie , Wszołek, Zbigniew K. , VandeVrede, Lawren , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.050692 Get It

AbstractBackgroundUp to 30% of frontotemporal dementia (FTD) cases are due to known pathogenic mutations (f‐FTD). Little is known about the factors that predict who will choose to learn their results. Upcoming clinical trials in f‐FTD may require disclosure prior to enrollment, even before symptom onset, and thus characterizing this sample is important. Furthermore, understanding the mood impacts of genetic disclosure may guide genetic counseling practice.MethodF‐FTD participants (n=568) from families with a known pathogenic mutation (MAPT, C9orf72, GRN) were enrolled through the ARTFL/LEFFTDS Longitudinal FTD Study (ALLFTD) and provided the opportunity for disclosure. Independent‐sample t‐tests compared demographic and psychosocial factors between participants who did and did not receive their results. In participants who were asymptomatic at baseline and follow up (n=199,177 with follow‐up), linear mixed effects modeling was used to investigate pre‐ to post‐disclosure changes in the 15‐item Geriatric Depression Scale (GDS).ResultOf participants from families with a known pathogenic genetic mutation, 47% received genetic disclosure. Of the asymptomatic subset (n=386), 36% know their mutation status. Of these asymptomatic learners, 46% received disclosure through the study, and the remainder learned their genetic status prior to study enrollment. None of the analyzed demographic or psychosocial factors (i.e., sex, age, education, having children) differed between learners and non‐learners (p’s > 0.05). In the longitudinal analysis of asymptomatic participants, learners showed a pre‐ to post‐increase of 0.31 GDS points/year (95%CI: ‐0.08, 0.69, p = 0.12), whereas non‐learners showed a slight decline (‐0.15 points/year, 95%CI: ‐0.36, 0.06, p = 0.16). This difference between slopes was statistically significant (0.46, 95%CI: 0.02, 0.89, p=0.04) but represents a small clinical effect. In asymptomatic learners, slopes did not differ based on mutation status (0.28, 95%CI: ‐0.66, 1.20, p=0.55). Conclusions were based on the estimates and full range of confidence intervals.ConclusionThe majority of asymptomatic research participants do not know their genetic status, which will be a consideration for clinical trials that require disclosure. No considered demographic factors were strongly associated with the decision to receive disclosure. The findings suggest that disclosure in asymptomatic participants has minimal impact on depressive symptoms regardless of genetic results.
Change in communication‐related participation in primary progressive apraxia of speech and aphasia
Martin, Peter R. , Josephs, Keith A. , Utianski, Rene L. , Duffy, Joseph R. , Botha, Hugo , Clark, Heather M.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.049719 Get It

AbstractBackgroundIndividuals with Primary Progressive Apraxia of Speech (PPAOS) have AOS as the initial and predominant symptom. Many develop aphasia and/or dysarthria later in the disease course. Past research has shown that patients with neurodegenerative AOS experience reduced participation in communication that is further exacerbated by co‐occurring language deficits. Previous studies suggest measures of disease severity do not necessarily correlate with measures of participation restrictions. The aim of this study was to describe changes in communication limitations in these patients over a one‐year interval, measured by 1) the patient via the Communicative Participation Item Bank (CPIB) and 2) the speech‐language pathologist via ASHA's Functional Communication Measures (FCMs) and an adapted Motor Speech Disorder (MSD) severity rating and determine if there are significant changes in these and other objective speech and language measures (e.g. Western Aphasia Battery‐Revised Aphasia Quotient, Apraxia of Speech Rating Scale‐3).MethodSeventeen patients (10 male) with progressive AOS were seen for a second visit approximately one year following the first visit. The measures collected at each visit were statistically compared. Correlations were calculated between the participation ratings and other clinical assessment measures at each visit and qualitatively compared.ResultThere were statistically significant differences in AOS and aphasia severity between visits. There were significant changes in clinical assessments, MSD severity rating, and all ASHA FCMs between visits, but not the CPIB. Comparison of correlations suggest the relationships among clinical and participation measures may change over time.ConclusionThe findings of this study support the use of patient reported outcome measures, like the CPIB, as they may better reflect the patient experience and associated changes in day‐to‐day functioning when other measures may simply index the progression of the disease.
Technology‐assisted caregiver matching to address isolation and stress
Lunde, Angela , Lunde, Angela M, Forsberg, Leah K. , Seifert, Sara J. , Kramer, K. , Knutson, Matthew , Lunde, Angela, Lunde, Angela, Miller, Joel K, Melius, Jodi L, Petersen, Ronald C. , Fields, Julie A. , Lunde, Angela M, Lunde, Angela, Lunde, Angela, Knopman, David S. , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.055692 Get It

AbstractBackgroundCaregiving for persons with dementia negatively impacts physical and mental health, including increased risk for chronic loneliness and isolation. This Phase I study aimed to recruit former and current dementia caregivers as engaged partners in the design of a unique, technology‐assisted pairing platform to match caregivers to one another for meaningful connection and support based on characteristics chosen by the caregivers themselves.MethodWe recruited thirty‐two caregivers to participate in two semi‐structured focus groups (audio recorded for qualitative analyses) and complete a survey to understand the characteristics desired in another caregiver for the purpose of emotional support. Participants interacted with a website prototype on their personal device and completed a user experience feedback form. An iterative process was used to design the website and matching questionnaire allowing participants to validate preferences and concerns. Website analytics were captured (e.g. time to answer each question, total time spent on the website).ResultThe efforts culminated in a website ‘look and feel’ that addressed the preferences and criticisms of study participants. Figure 1 shows the home page slider inviting caregivers to join (images 1‐3) and describes the matching process (4); the caregiver answers up to 34 questions to create a profile (5‐7) and the website provides a list of caregivers that best match criteria (8). Overall, 87% of study participants rated a high level of comfort with completing the personal profile questions; 82% felt confident the questions asked would lead to a good match. An algorithm to match caregivers was created using the profile questions which asked participants to self‐select and then rank the characteristics of highest importance. Good and poor matches are scored by the algorithm, with 1 being a “perfect” match (Figure 2). In the current cohort, each participant had at least one match that scored 0.708 or higher.ConclusionOur study established interest in a technology assisted peer‐to‐peer caregiver matching program that is a potential low‐cost, high‐impact resource. The study resulted in a set of matching characteristics and an algorithm prototype within a user influenced website and will be further tested in Phase 2. Research supported from NIA of the NIH.
Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration
Banga, Yasmin B, Lai, Yujung, Kim, Priscilla , Boxer, Adam L. , Rosen, Howard J. , Forsberg, Leah K. , Heuer, Hilary W. , Brushaber, Danielle , Bordelon, Yvette , Dickerson, Brad C., Dickinson, Susan, Faber, Kelley , Fagan, Anne M. , Fields, Julie A. , Fishman, Ann, Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Jonathan, Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Karydas, Anna M., Kaufer, Daniel , Kramer, Joel H. , Kornak, John , Lagone, Emma, Ljubenkov, Peter A. , Lucente, Diane , Mackenzie, Ian R. , Manoochehri, Masood , Masdeu, Joseph C. , McGinnis, Scott, Mendez, Mario F, Miyagawa, Toji , Nelson, K. , Onyike, Chiadi U. , Pantelyat, Alex, Pearlman, Rodney , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Sabbagh, Marwan N. , Salmon, David P. , Savica, Rodolfo , Staffaroni, Adam M. , Syrjanen, Jeremy A. , Tatton, Nadine , Taylor, Jack C. , Weıntraub, Sandra , Wheaton, Diana, Wong, Benjamin , Boeve, Bradley F. , Appleby, Brian S. , Biernacka, Joanna M. , Botha, Hugo , Bozoki, Andrea C , Brannelly, Patrick , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Foroud, Tatiana , Gendron, Tania F. , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Knopman, David S. , Kremers, Walter K. , Kukull, Walter A. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Mendez, Mario F, Miller, Bruce L. , Nelson, Kevin M, Pascual, Belén , Pottier, Cyril , Rexach, Jessica E. , Roberson, Erik D. , Rojas, Julio C. , Seeley, William W. , Tartaglia, Maria Carmela , Toga, Arthur W. , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.052495 Get It

AbstractBackgroundFrontotemporal lobar degeneration (FTLD) refers to a group of neurodegenerative conditions, affecting the frontal and/or temporal lobes. Ongoing research has provided insight into developing clinical trials for FTLD and key clinical measures such as structural MRI. To inform clinical trial design and optimize participation, it is imperative to explore facilitators and barriers for potential candidates.ObjectiveThe objective of this study is to explore facilitators and barriers to participating in future clinical trials for FTLD.MethodsAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) are observational studies focused on characterizing FTLD syndromes in preparation for clinical trials. The 584 participants enrolled across 18 research sites in the United States and Canada completed a survey assessing interest in clinical trial participation.Results29% of respondents self‐reported as patients (63±10 years), 26% self‐reported as caregivers answering on behalf of patients (65±10 years), and 45% self‐reported as healthy but at risk for FTLD (48±14 years). Travel reimbursement was the most common factor reported to positively influence participation (≧66%), with the healthy but at risk group showing the strongest endorsement (83%). Cost and time involved in travel were possible barriers for about half of the patients (48%) and healthy but at risk respondents (53%). The respondents value receiving feedback on the study findings (≧80%) and being informed of their individual disease progression (≧75%). Particularly, keeping participation confidential was very important for the healthy but at risk group (62%). In regard to research assessments, most participants demonstrated a high interest in physical and neurological exams at a research center (≧87%) whereas only half were interested in doing more invasive procedures such as the lumbar puncture (≧52%). Overall, respondents showed a positive attitude and support for research participation (≧77%) and trusted that their health information would remain confidential in a clinical trial (≧53%).ConclusionsFavorable attitudes and interest towards medical research exist among participants. To optimize participation, clinical trials should allocate funding for travel and involve participants in feedback about study results and their disease progression. Alternatives to invasive assessments may increase participation.
Longitudinal effects of behavioral interventions: A comparison using a propensity score matching model
Ying, Gelan , Chandler, Melanie , Shandera‐Ochsner, Anne L., Locke, Dona E.C. , Smith, Glenn E.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.049537 Get It

AbstractBackgroundBehavioral interventions are often recommended for persons with mild cognitive impairment (MCI). The Healthy Action to Benefit Independence & Thinking® Program (HABIT) has been shown to benefit activities of daily living (ADL) and self‐efficacy in patients at 6‐ and 12‐months post intervention. However, to date, the findings have been limited by comparison to a relatively small, untreated control group. This study attempted to explore HABIT ADL outcomes compared to a large, presumably untreated Alzheimer's Disease Neuroimaging Initiative (ADNI) MCI cohort.MethodA total of 767 participants with MCI were selected from the ADNI database, whereas 478 participants with MCI were recruited from the HABIT IRB approved research registry. Functional outcomes were assessed with informant‐based measures ‐ Functional Activities Questionnaire (FAQ) and Everyday Cognition scale (ECOG) memory and total scores – at both 6‐month‐ and 12‐month‐follow‐ups. After near‐neighbor propensity score matching with a caliper of 0.2, 288 participants from each group were matched for the FAQ, and 333 were matched for the ECOG scores. Latent growth curve models were used to test the hypothesis that the HABIT program might delay functional decline in patients with MCI.ResultAfter matching HABIT group continued to show higher initial scores on FAQ (b=.849, p=.013), and ECOG memory (b=.200, p=.004) and total scores (b=1.115, p<.001) compared to the ADNI group. Although an increase in scores was observed in both groups for each functional outcome, the slopes were steeper for the HABIT group for FAQ (b=1.194, p<.001), ECOG memory (b=.073, p=.019) and ECOG total (b=.383, p=.007).ConclusionContrary to our hypothesis, in this non‐randomized study, partners of HABIT participants with MCI reported more rapid functional decline compared to those in an imaging study. This discrepancy could be due to the HABIT group’s higher baseline impairment level even after matching. Furthermore, patients with perceived more rapid decline may be more likely to seek interventions relative to those who elect to participate in a non‐interventional imaging study. In addition, the intervention sessions could prime the partners to be more scrupulous and aware when rating functional assessments. Additional randomized research may help add clarity to these findings.
Atrial fibrillation in partial anomalous pulmonary venous return: right atrial drainage from one vein and epicardial conduction from another vein
Bhalla, Jaideep Singh , Zyl, Martin van , Madhavan, Malini , Bhalla, Jaideep

Mayo Clinic

EP Europace | February 1, 2022 | Volume: 24 | Issue: 9 | Pages: 1459-1459

10.1093/europace/euac006 | PMID 35357427 Get It